Skip to main content

Table 1 Characteristics of 216 patients with primary MDS

From: Elevated mature monocytes in bone marrow accompanied with a higher IPSS-R score predicts a poor prognosis in myelodysplastic syndromes

Variable All patients Elevated PMMBM group Normal group P-value
Age, years median (range) 61 (16–90) 62 (24–83) 61 (16–90) 0.971
Male/Female, n 117/99 23/13 94/86 0.200
BM blast, % median (range) 3.5 (0–19.5) 8.8 (0–19.5) 3.0 (0–19.5) < 0.0001
PMMBM, % median (range) 3.0 (0–24.0) 7.5 (6.5–24.0) 3.0 (0–6.0) < 0.0001
Peripheral Blood
 NE, × 109/L median (range) 1.2 (0–7.4) 0.8 (0–6.6) 1.2 (0.1–7.4) 0.022
 HB, g/dl median (range) 7.7 (2.2–14.2) 8.6 (2.9–13.4) 7.6 (2.2–14.2) 0.463
 PLT, ×109/L median (range) 51.5 (2.0–340.0) 42.0 (6.0–332.0) 55.0 (2.0–340.0) 0.143
 Monocytes, ×109/L median (range) 0.2 (0–0.8) 0.2 (0–0.7) 0.2 (0–0.8) 0.102
 Monocytes, % median (range) 7.1 (0.4–39.0) 10.1 (0.7–27.2) 6.3 (0.4–39.0) < 0.0001
 SF, μg/L median (range) 304.4 (5.5–2612.0) 242.0 (9.5–1447.6) 307.0 (5.5–2612.0) 0.749
 β2-MG, mg/L median (range) 1.8 (0–12.6) 2.2 (0.4–5.5) 1.8 (0–12.6) 0.058
 LDH, IU/L median (range) 207.0 (54.0–1083.0) 215.0 (123.0–616.0) 203.5 (54.0–1083.0) 0.373
 Cytogenetic abnormalities, % (n/n) 45.1 (83/184) 50.0 (15/30) 44.2 (68/154) 0.556
WHO classification     0.005
 MDS-SLD, % (n/n) 13.4 (29/216) 8.3 (3/36) 14.4 (26/180)  
 MDS-MLD, % (n/n) 27.8 (60/216) 14.0 (5/36) 30.6 (55/180)  
 MDS-RS, % (n/n) 6.0 (13/216) 0 (0/36) 7.2 (13/180)  
 MDS-EB1, % (n/n) 21.8 (47/216) 22.2 (8/36) 21.7 (39/180)  
 MDS-EB2, % (n/n) 22.2 (48/216) 47.2 (17/36) 17.2 (31/180)  
 MDS-del(5q), % (n/n) 0.5 (1/216) 0 (0/36) 0.6 (1/180)  
 MDS-U, % (n/n) 8.3 (18/216) 8.3 (3/36) 8.3 (15/180)  
IPSS-R cytogenetic
risk
    0.756
 Very good, % (n/n) 0.5 (1/185) 0 (0/30) 0.5 (1/155)  
 Good, % (n/n) 66.5 (123/185) 56.7 (17/30) 66.5 (106/155)  
 Intermediate, %(n/n) 20.0 (37/185) 26.7 (8/30) 20.0 (29/155)  
 Poor, % (n/n) 2.7 (5/185) 3.3 (1/30) 2.7 (4/155)  
 Very poor, % (n/n) 10.3 (19/185) 13.3 (4/30) 10.3 (15/155)  
IPSS-R risk     0.025
 Very low, % (n/n) 7.6 (14/185) 0 (0/30) 9.0 (14/155)  
 Low, % (n/n) 22.2 (41/185) 6.6 (2/30) 25.2 (39/155)  
 Intermediate, % (n/n) 34.6 (64/185) 36.7 (11/30) 34.2 (53/155)  
 High, % (n/n) 17.8 (33/185) 30.0 (9/30) 15.5 (24/155)  
 Very high, % (n/n) 17.8 (33/185) 26.7 (8/30) 16.1 (25/155)  
 Gene mutation, % (n/n) 68.8 (55/80) 77.8 (7/9) 67.6 (48/71) 0.811
 Leukemia transformation, % (n/n) 13.0 (28/216) 22.2 (8/36) 11.1 (20/180) 0.070
  1. Abbreviations: BM bone marrow, PMMBM the percentage of mature monocyte in bone marrow, NE neutrophil, HB hemoglobin, PLT platelet, LDH lactate dehydrogenase, MDS-SLD MDS with single lineage dysplasia, MDS-MLD MDS with multilineage dysplasia, MDS-RS MDS with ring sideroblasts, MDS-EB MDS with excess blasts, MDS-U unclassifiable, IPSS-R Revised International Prognostic Scoring System